Our study also shows that PCLP1 diminishes obinutuzumab-induced cell death, which has been recently proven to be effective in the treatment of patients with rituximab-refractory indolent non-Hodgkin lymphoma [53]. Here, PODXL is linked to non-Hodgkin lymphoma.